TuisHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Vorige sluiting
€25,85
Dagwisseling
€25,67 - €25,67
Jaarwisseling
€19,52 - €36,69
Markkapitalisasie
3,58 mjd USD
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Inkomste | — | — |
Bedryfskoste | 126,19 m | 28,63% |
Netto inkomste | -125,30 m | -357,42% |
Netto winsgrens | — | — |
Wins per aandeel | -1,02 | -326,67% |
EBITDA | -121,67 m | -339,34% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 520,91 m | 8,30% |
Totale bates | 955,15 m | 7,16% |
Totale aanspreeklikheid | 459,74 m | 7,87% |
Totale ekwiteit | 495,40 m | — |
Uitstaande aandele | 124,20 m | — |
Prys om te bespreek | 6,63 | — |
Opbrengs op bates | -39,90% | — |
Opbrengs op kapitaal | -43,18% | — |
Kontantvloei
Netto kontantverandering
(USD) | Mrt. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -125,30 m | -357,42% |
Kontant van bedrywe | -92,38 m | -191,68% |
Kontant van beleggings | -268,94 m | -645,70% |
Kontant van finansiering | 430,78 m | 82 741,73% |
Netto kontantverandering | 69,49 m | 203,27% |
Beskikbare kontantvloei | -91,82 m | -262,49% |
Meer oor
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Gestig
01 Jan. 2004
Hoofkwartier
Webwerf
Werknemers
525